Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
Mauna Kea Technologies Reports First Cellvizio(R) System Sales in Japan and New Clinical Research on Digestive Cancers and Disorders
Two Leading Japanese Physicians Acquire Cellvizio Systems to Gain New Understanding of Stomach Cancer and Functional Gastrointestinal Diseases; Their Clinical Research Could Lead to New Clinical Data, Demonstrating That Cellvizio Can Help Speed Diagnosis

PARIS -- (Marketwire) -- 01/30/13 -- Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, reported its first Cellvizio system sales in Japan, the world's second largest healthcare market.

Physicians at prestigious Schools of Medicine in Japan, including the Hirosaki University Graduate School of Medicine in Aomori, have acquired Cellvizio systems to gain new understanding of stomach, pancreatic and esophageal cancers, as well as common functional gastrointestinal and motility disorders such as irritable bowel syndrome (IBS), gastro-esophageal reflux disease (GERD) and chronic constipation. Stomach cancer is second most prevalent kind of cancer in Asia and the leading cause of cancer in men in the region, according to the World Health Organization. An estimated 736,000 people die from stomach cancer each year, making it the second leading cause of cancer death worldwide.(i)

"Japan is the world's second largest healthcare market and the most advanced endoscopy market. These two installations at leading Japanese institutions represent a significant milestone for the company," said Sacha Loiseau, PhD, CEO of Mauna Kea Technologies. "The clinical research that will come out of them will play an important role in the development of new clinical data showing that optical biopsies can help speed the diagnosis and treatment of digestive diseases that are particularly prevalent throughout Japan and the rest of Asia. We are currently in the process of filing for regulatory approval of Cellvizio in Japan which, once obtained, will allow us to significantly broaden our footprint in the Asia Pacific region where we already have 38 Cellvizio systems installed."

Cellvizio was recently used for the first time in Japan, in collaboration with German physicians, to directly view the enteric nervous system of the digestive tract during an endoscopic procedure. Their early findings, which open the door to using optical biopsies as a tool to improve how physicians diagnose and treat functional GI and motility disorders, were recently published online in the medical journal, Gastroenterology, the leading journal in the digestive field.(ii)

Kenichi Hakamada, Professor and Chairman of the Department of Gastroenterological Surgery at Hirosaki University Graduate School of Medicine, will use Cellvizio to visualize cellular structures of various digestive cancers.

Independent clinical studies utilizing optical biopsies with Cellvizio will be launched during the second quarter of 2013. Both physicians acquired their Cellvizio systems after obtaining a "Yakkan Shoumei" import certificate that allows physicians to import unapproved medical devices into the country. They will both participate in the International Conference of Cellvizio Users (ICCU) in April 2013 in Istanbul in order to share their findings with the optical biopsy community.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI tract, biliary and pancreatic ducts and lungs.

For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in Mauna Kea Technologies ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorité des marches financiers ("AMF") granted its visa number 11-236 on June 20, 2011, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

(i) GLOBOCAN 2008 (IARC) Section of Cancer Information (22/1/2013)
(ii) Sumiyama K, Kiesslich R, Ohya TR, Goetz M, Tajiri H. In vivo imaging of enteric neuronal networks in humans using confocal laser endomicroscopy. Gastroenterology. 2012;143(5):1152-3.

United States
Erich Sandoval
Tel: +1 917 497 2867
esandoval@lazarpartners.com

Mauna Kea Technologies
Alexander Bryson
Marketing Communications and Brand
Manager
Tel: +33 (0) 1 70 08 09 92
alexander@maunakeatech.com

France and Europe
NewCap.
Investor Relations and Financial Communication
Pierre Laurent / Florent Alba
Tel: +33(0)1 44 71 94 94
maunakea@newcap.fr

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest AJAXWorld RIA Stories
At the beginning of the book the authors say they created this book to be used in a classroom setting. I agree that it is a great book for the classroom, but I would also recommend it to anyone who wants to learn about the current Agile methodologies. It does what the title of th...
As an enterprise and software architect the one thing I hate most about my job is documentation, yet the importance of doing documentation on sizable projects is what I find myself preaching about the most. One reason I understand the importance of documentation is that I came f...
The premiere issue of the Internet of @ThingsExpo Newsletter contains highlights of the hottest sessions and speakers from Internet of @ThingsExpo, Call for Papers information, and sponsorship opportunities.
“At Cloud Expo in NYC last week I sat in on the Internet of Things power panel and then presented about how to monetize the Internet of Things. The room was packed, standing room only and I stuck around for a full 30 minutes afterwards answering questions before I had to tear mys...
Express Logic, Inc., the worldwide leader in royalty-free real-time operating systems (RTOSes), introduces X-Ware™, an integrated, optimized, comprehensive middleware solution that provides a solid foundation for Internet of Things (IoT) development. X-Ware consists of Express Lo...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON Featured Whitepapers
ADS BY GOOGLE